In addition to NSCLC, research has indicated that the activation of the HGF/c-MET pathway is associated with increased PD-L1 expression in hepatocellular carcinoma following cisplatin treatment, downstream of the PI3K/Akt and MET/ERK pathways [190]. This evidence concerns the gene MET and hepatocellular carcinoma.